Extremely Preterm Infant Admissions Within the SafeBoosC-III Consortium During the COVID-19 Lockdown
暂无分享,去创建一个
G. Greisen | A. Mathur | M. Fumagalli | G. Naulaers | M. Couce | D. Gkentzi | A. El-Khuffash | G. H. Hahn | G. Pichler | L. Chalak | M. Wilińska | E. Mastretta | M. Baserga | S. A. | K. Sarafidis | R. Del Río | E. Ergenekon | M. Stocker | T. Karen | M. Çetinkaya | E. Hatzidaki | B. Królak-Olejnik | E. Dempsey | L. Arruza | A. Pellicer | M. Hansen | M. I. Rasmussen | S. Fredly | A. Memişoğlu | H. Özkan | Ping Wang | T. Szczapa | I. Sadowska-Krawczenko | Marie Isabel Rasmussen | A. Heuchan | J. Tkaczyk | L. Cornette | C. Lecart | L. Bender | E. Papathoma | H. Reigstad | J. Širc | Salvador Piris-Borregas | R. Viellevoye | J. De Buyst | M. Alsina | H. Fuchs | O. Otero Vaccarello | Elżbieta Rafińska-Ważny | Zhang Peng | J. de Buyst
[1] S. Lorch,et al. Changes in Preterm Birth Phenotypes and Stillbirth at 2 Philadelphia Hospitals During the SARS-CoV-2 Pandemic, March-June 2020. , 2020, JAMA.
[2] C. Dunne,et al. Unprecedented reduction in births of very low birthweight (VLBW) and extremely low birthweight (ELBW) infants during the COVID-19 lockdown in Ireland: a ‘natural experiment’ allowing analysis of data from the prior two decades , 2020, BMJ Global Health.
[3] A. Dorn. COVID-19 and readjusting clinical trials , 2020, The Lancet.
[4] Aaron van Dorn. COVID-19 and readjusting clinical trials , 2020, The Lancet.
[5] D. Hougaard,et al. Danish premature birth rates during the COVID-19 lockdown , 2020, Archives of Disease in Childhood.
[6] J. Lawn,et al. Effect of the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality outcomes in Nepal: a prospective observational study , 2020, The Lancet Global Health.
[7] I. Reiss,et al. Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study , 2020, The Lancet Public Health.
[8] C. Dunne,et al. Reduction in preterm births during the COVID-19 lockdown in Ireland: a natural experiment allowing analysis of data from the prior two decades. , 2020, medRxiv.
[9] G. Dimitriou,et al. Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial , 2019, Trials.
[10] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[11] A. Akobeng. Understanding type I and type II errors, statistical power and sample size , 2016, Acta paediatrica.
[12] A. Banerjee,et al. Hypothesis testing, type I and type II errors , 2009, Industrial psychiatry journal.
[13] T. Hale,et al. Oxford COVID-19 Government Response Tracker , 2020 .
[14] Marta Elena Losa-Iglesias,et al. Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.
[15] Isabelle Boutron,et al. A revised tool for assessing risk of bias in randomized trials , 2016 .